NCT07504796 ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Status RECRUITING Phase PHASE4
NCT06816927 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab Status RECRUITING Phase PHASE2
NCT06683755 Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06561386 A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% Status RECRUITING Phase PHASE3
NCT06400264 Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) Status WITHDRAWN Phase PHASE2
NCT06325683 Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Status SUSPENDED Phase PHASE2
NCT06237920 Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab Status RECRUITING Phase PHASE2
NCT06029270 Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Status RECRUITING Phase PHASE2
NCT05987241 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Status RECRUITING Phase PHASE2/PHASE3
NCT05704647 Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases Status RECRUITING Phase PHASE2
NCT05498480 Study of Relatlimab in Combination With Nivolumab in Chinese Participants Status COMPLETED Phase PHASE1
NCT05347212 Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05337137 A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT05255601 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT05034536 PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04953104 ARID1A and/or KDM6A Mutation and CXCL13 Expression Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04913922 Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML Status RECRUITING Phase PHASE2
NCT04658147 Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04623775 A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Status ACTIVE_NOT_RECRUITING Phase PHASE2